Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
88.85
-0.70 (-0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
BioNTech to Host Innovation Series R&D Day on November 11, 2025
October 28, 2025
From
BioNTech SE
Via
GlobeNewswire
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
October 27, 2025
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside
↗
September 08, 2025
Via
Stocktwits
What Analysts Are Saying About BioNTech Stock
↗
September 08, 2025
Via
Benzinga
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
October 27, 2025
From
BioNTech SE
Via
GlobeNewswire
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
↗
October 25, 2025
Both companies are monsters in their industry and are poised to thrive.
Via
The Motley Fool
Topics
Government
Intellectual Property
World Trade
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
October 22, 2025
From
BioNTech SE
Via
GlobeNewswire
Beyond The Numbers: 7 Analysts Discuss BioNTech Stock
↗
October 10, 2025
Via
Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...
Via
MarketMinute
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
↗
October 08, 2025
These biotechs could finally come into their own by the end of the decade.
Via
The Motley Fool
Topics
Government
World Trade
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
October 02, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
October 02, 2025
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...
Via
MarketMinute
Topics
Artificial Intelligence
Derivatives
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
↗
October 01, 2025
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.
Via
The Motley Fool
Topics
Artificial Intelligence
Government
World Trade
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
September 23, 2025
From
BioNTech SE
Via
GlobeNewswire
Why BioNTech Stock Bumped Higher Today
↗
September 22, 2025
Investors were cheered by two pieces of good news concerning the biotech's most famous product.
Via
The Motley Fool
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
↗
September 19, 2025
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.
Via
Investor's Business Daily
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut
↗
September 18, 2025
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.
Via
Investor's Business Daily
Topics
Government
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
September 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax
↗
September 16, 2025
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.
Via
Benzinga
Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks
↗
September 15, 2025
Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised...
Via
Chartmill
Topics
Artificial Intelligence
Economy
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
↗
September 14, 2025
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.
Via
Benzinga
Topics
Earnings
Why BioNTech Stock Sank by More Than 7% Today
↗
September 12, 2025
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..
Via
The Motley Fool
Topics
Death
Government
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
↗
September 12, 2025
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.
Via
Benzinga
Topics
Government
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
↗
September 10, 2025
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.
Via
Investor's Business Daily
Topics
Government
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
↗
September 08, 2025
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.
Via
Benzinga
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
↗
September 08, 2025
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.
Via
Benzinga
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
September 08, 2025
From
BioNTech SE
Via
GlobeNewswire
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
↗
September 08, 2025
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.
Via
Investor's Business Daily
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
September 08, 2025
From
Pfizer Inc.
Via
Business Wire
Why BioNTech Stock Crushed the Market Today
↗
September 05, 2025
The company might be close to commercializing its most advanced pipeline program.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.